Effect of CYP2C9 and VKORC1 genotype on inter-individual warfarin dose - A prospective study in Chinese populatio
Not Applicable
Completed
- Conditions
- ot applicableNot ApplicableNot applicable
- Registration Number
- ISRCTN54178709
- Lead Sponsor
- ational Natural Science Foundation of China
- Brief Summary
2009 results in https://pubmed.ncbi.nlm.nih.gov/19177029/ (added 10/06/2021)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 422
Inclusion Criteria
1. Patients who will initiate warfarin administration
2. Aged 18 years or more
3. Written informed consent to participate in the study
Exclusion Criteria
1. Patients with previous and current liver disease
2. Renal failure (creatinine greater than 106 µmo/L)
3. Base coagulant response time (INR) is 1.4 or more
4. Patients using any other known drugs that related to CYP2C9
5. Use of warfarin in the past three months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Difference in stable warfarin doses among patients with genotypes CYP2C9 and VKORC1<br> 2. An algorithm of stable warfarin dose established using multiple linear-regression equation<br> 3. To assess the feasibility of the algorithm for treatment group compared to control group on:<br> 3.1. Days until a stable therapeutic INR (2.0-3.0)<br> 3.2. Days until an adverse outcome<br>
- Secondary Outcome Measures
Name Time Method <br> 1. INR, measured every day during hospitalization and twice a week after discharge<br> 2. Warfarin dose, recorded every day<br> 3. Adverse outcome, recorded every day<br>